ImmuCell Corp Appoints New Directors, One Departs
Ticker: ICCC · Form: 8-K · Filed: Nov 4, 2025 · CIK: 811641
| Field | Detail |
|---|---|
| Company | Immucell Corp /De/ (ICCC) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.10 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, management
TL;DR
ImmuCell's board shakes up: McGeary out, Barchi and Smith in. New blood incoming.
AI Summary
On October 29, 2025, ImmuCell Corporation reported the departure of Director Dr. Michael J. McGeary. The filing also noted the election of two new directors, Dr. Robert J. Barchi and Mr. David M. Smith, to the Board of Directors. These changes are effective immediately.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing primarily concerns routine board changes and does not indicate significant financial distress or operational disruption.
Key Players & Entities
- ImmuCell Corporation (company) — Registrant
- Dr. Michael J. McGeary (person) — Departing Director
- Dr. Robert J. Barchi (person) — Newly Elected Director
- Mr. David M. Smith (person) — Newly Elected Director
- October 29, 2025 (date) — Effective date of changes
FAQ
Who has departed from ImmuCell Corporation's Board of Directors?
Dr. Michael J. McGeary has departed from the Board of Directors.
Who have been elected as new directors to ImmuCell Corporation's Board?
Dr. Robert J. Barchi and Mr. David M. Smith have been elected as new directors.
What is the effective date of these board changes at ImmuCell Corporation?
The changes are effective as of October 29, 2025.
What is ImmuCell Corporation's state of incorporation?
ImmuCell Corporation is incorporated in Delaware.
What is ImmuCell Corporation's principal executive office address?
The principal executive offices are located at 56 Evergreen Drive, Portland, Maine 04103.
Filing Stats: 687 words · 3 min read · ~2 pages · Grade level 10.1 · Accepted 2025-11-04 16:08:55
Key Financial Figures
- $0.10 — ge on which registered Common Stock , $0.10 par value per share ICCC The Nasdaq
Filing Documents
- iccc20251103_8k.htm (8-K) — 35KB
- ex_882751.htm (EX-99.1) — 12KB
- 0001437749-25-033017.txt ( ) — 178KB
- iccc-20251029.xsd (EX-101.SCH) — 3KB
- iccc-20251029_def.xml (EX-101.DEF) — 11KB
- iccc-20251029_lab.xml (EX-101.LAB) — 15KB
- iccc-20251029_pre.xml (EX-101.PRE) — 11KB
- iccc20251103_8k_htm.xml (XML) — 3KB
01. Exhibits
Item 9.01. Exhibits. (d) Exhibits . The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed: 99.1 Press Release of the Company dated November 4, 2025. 104 Cover page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUCELL CORPORATION Date: November 4, 2025 By: /s/ Timothy C. Fiori Timothy C. Fiori Chief Financial Officer 2 Exhibit Index Exhibit No. Description 99.1 Press Release of the Company dated November 4 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 3